Corpus ID: 59548157

Bioequivalence Study of Tadalafil Tablets in Healthy Chinese Volunteers under Fasting Conditions

@inproceedings{Ren2018BioequivalenceSO,
  title={Bioequivalence Study of Tadalafil Tablets in Healthy Chinese Volunteers under Fasting Conditions},
  author={Guanghui Ren and Zhiying Qin and HuitingSong and Y. Tan and Yonghan Wang and Danni Hao and Yanglu and N. Li and D. Zhao and X. Chen},
  year={2018}
}
Approved by FDA in 2003 for the treatment of penile erectile dysfunction and in 2009 for the treatment of the pulmonary arterial hypertension, tadalafil is a selective, reversible inhibitor of PDE5 and it is the active compound of Cialis® [1,2].The therapeutic dose of tadalafil for the treatment of penile erectile dysfunction ranges from 2.5 to20mg, daily. While in the treatment of pulmonary arterial hypertension the doses of tadalafil usually at 40mg. It has been confirmed that tadalafil could… Expand

Figures, Tables, and Topics from this paper

References

SHOWING 1-7 OF 7 REFERENCES
Tadalafil pharmacokinetics in healthy subjects.
  • 207
Validated UPLC-MS/MS assay for the determination of synthetic phosphodiesterase type-5 inhibitors in postmortem blood samples.
  • 12
Quantitation of tadalafil in human plasma using a sensitive and rapid LC-MS/MS method for a bioequivalence study
  • 7
Design and Analysis of Bioavailability and Bioequivalence Studies, (3rd edn), CRC Press, Florida, USA
  • 2008